Gastric Cancer Surge: Are You Prepared?
Combating Gastric Cancer: The Crucial Role of Early H. pylori Intervention
Table of Contents
Gastric cancer, a significant global health concern, is largely preventable, with early intervention against the bacterium Helicobacter pylori (H. pylori) being a cornerstone of prevention strategies. Dr. José María Remesal Gisbert, a leading expert and researcher, emphasizes that while H. pylori infection is typically acquired in childhood, the gastric cancer it can lead to often manifests decades later, usually after the age of 50.
understanding the H. pylori Pathway to Cancer
H. pylori infection is a gradual process that progressively damages the stomach lining. This damage follows a well-defined pathological sequence:
Superficial Gastritis: The initial stage, characterized by inflammation of the stomach’s surface.
Atrophic Gastritis: A more advanced stage where the stomach lining thins and loses it’s functional glands.
Intestinal Metaplasia: The stomach lining begins to resemble the lining of the intestine, a precancerous change.
Dysplasia: The final precancerous stage, involving abnormal cell growth, before the development of invasive cancer.
“If we treat the infection early,before these changes occur,we can prevent gastric cancer,” Dr. Gisbert explains.This highlights the critical importance of timely diagnosis and eradication of H. pylori.
Screening Strategies and Practice Gaps in Spain
Despite the clear link between H.pylori and gastric cancer, the incidence of this cancer in Spain remains relatively low, with fewer than 10 cases per 100,000 people annually. Consequently, widespread screening of asymptomatic individuals for H. pylori is not currently deemed cost-effective or necesary nationwide. “In countries with higher gastric cancer rates, H. pylori screening would be cost-effective,” Dr. Gisbert notes. “But in Spain, it’s not clearly justified.”
Though, a study led by Dr. Gisbert, assessing the management of H. pylori infections by Spanish gastroenterologists outside the European H. pylori Registry, revealed significant practice gaps. These findings, published in the journal Helicobacter, underscore areas where clinical practice could be improved:
Incomplete Testing: A notable 17% of specialists failed to test for H. pylori in patients presenting with gastrointestinal bleeding from peptic ulcers.
Delayed Treatment: 35% of specialists did not initiate treatment for H. pylori at the time of diagnosis in these high-risk cases.
Limited Awareness of Resistance: Only 25% of gastroenterologists were aware of local clarithromycin resistance rates, a key factor in treatment efficacy.
Inadequate Follow-up: A mere 37% regularly assessed the effectiveness of eradication treatments,crucial for ensuring successful elimination of the bacteria. Penicillin Allergy Oversight: A significant 74% of specialists did not confirm penicillin allergy before prescribing treatment, perhaps leading to adverse reactions.
Family History Neglect: A concerning 32% did not investigate first-degree relatives of patients diagnosed with gastric cancer, missing an opportunity for early detection and intervention in at-risk families.
The future of Gastric Cancer Prevention: Vaccination and Enhanced Interventions
The authors of the study conclude that given the largely preventable nature of gastric cancer, more proactive intervention and control programs are essential, notably in high-resource East Asian countries where gastric cancer rates are higher.
The development of an H. pylori vaccine is seen as a significant advancement in the fight against gastric cancer. Similar to the impact of human papillomavirus (HPV) vaccines on cervical cancer prevention and hepatitis B vaccines on reducing liver cancer risk, an H. pylori vaccine could revolutionize prevention. Vaccination is recognized as one of the most context-responsive and adaptable prevention strategies, especially beneficial in low- and middle-income settings where a substantial burden of H. pylori-attributable gastric cancer is anticipated.
Dr. Gisbert reported no conflicts of interest related to this research.